Mulligan Seamus's Form 4 filing
Jazz Pharmaceuticals plc (JAZZ) · filed May 13, 2025
- Accession no.
- 0001765581-25-000042
- Filed
- May 13, 2025
- Trade date
- May 9-12, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $9.99M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mulligan SeamusCIK 0001536639 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 9, 2025 | Ordinary Shares | PPurchaseAcquired | +80,684 | $98.10F1 | +$7,915,100.4 | 80,684 | Indirect | |
| May 9, 2025 | Ordinary Shares | PPurchaseAcquired | +19,216 | $98.91F3 | +$1,900,654.56 | 99,900 | Indirect | |
| May 9, 2025 | Ordinary Shares | PPurchaseAcquired | +100 | $99.71 | +$9,971 | 100,000 | Indirect | |
| May 12, 2025 | Ordinary Shares | PPurchaseAcquired | +1,621 | $103.00F4 | +$166,963 | 101,621 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $97.56 to $98.5542. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
Referenced by the price of 1 transaction in Table I.
- F3
Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $98.56 to $99.47. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
Referenced by the price of 1 transaction in Table I.
- F4
Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $102.97 to $103.00. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
Referenced by the price of 1 transaction in Table I.